期刊文献+

赖氨酰氧化酶样-4与尿激酶型纤溶酶原激活物及其受体在人宫颈癌细胞中的表达及意义 被引量:2

Expressions and significance of lysyloxidase-like 4 and uPA/uPAR in human cervical carcinoma cell lines
下载PDF
导出
摘要 目的探讨赖氨酰氧化酶样基因-4(LOXL4)、尿激酶型纤溶酶原激活物(uPA)及其受体(uPAR)在人宫颈癌细胞株中的表达。方法采用半定量RT-PCR方法检测人宫颈癌细胞株Hela、ME180、HCC94中LOXL4、uPA和uPAR mRNA的表达,同时运用Western blot技术检测各细胞中LOXL4蛋白的翻译情况。结果 LOXL4mRNA在三株人宫颈癌细胞株中表达差异有统计学意义(P<0.01),其中在Hela细胞株中表达浓度最高,ME180细胞株表达浓度次之,而HCC94细胞株表达浓度最低;而uPA、uPAR mRNA表达浓度水平在HCC94细胞中最高,明显高于Hela、ME180细胞的表达浓度水平(P<0.05)。结论 LOXL4、uPA、uPAR基因表达可能与宫颈癌细胞的侵袭和迁移有关。 Objective To investigate the expression of lysyloxidase-like 4(LOXL4),urokinase plasminogen activator(uPA),and urokinase plasminogen activator receptor(uPAR)in human cervical carcinoma cell lines.Methods LOXL4,uPA and uPAR mRNA expression levels in cell lines Hela,ME180,and HCC94were investigated by the method of reverse transcription PCR(RT-PCR),determination of LOXL4protein levels in cell lines Hela,ME180,and HCC94with western blot.Results Differential expressions were found both LOXL4mRNA and protein levels of all the three human cervical carcinoma cells(P〈0.01).Hela had the highest expression,and was followed by ME180and HCC94,respectively.The expression levels of uPA and uPAR mRNA were highest in HCC94cell lines,and significantly higher than that of Hela and ME180cell lines(P〈0.05).Conclusion The expression of LOXL4mRNA,uPA and uPAR mRNA in human cervical carcinoma cell lines might be associated with invasion and metastasis of cervical cancer cells.
出处 《福建医药杂志》 CAS 2014年第3期1-4,共4页 Fujian Medical Journal
基金 福建省自然科学基金资助项目(2012J01310) 福州市科技计划项目(2010-S-88)
  • 相关文献

参考文献10

  • 1Wu GuoJun,Guo ZhongMin,Chang XiaoFei,et al.LOXL1 and LOXL4 are epigenetically silenced and can inhibit ras/ex tracellular signal regulated kinase signaling pathway in human bladder cancer[J].Adv Cancer Res,2007,67 (9):4123-4129.
  • 2Duffy M J,Maguire T M,Mcdermott E W,et al.Urokinase plasminogen activator:a prognostic marker in multiple types of cancer[J].EurJ SurgOncol,1999,71 (2):130-135.
  • 3马国中,王继生.蛋白质组学的临床实验与应用[J].中国实用医药,2008,3(30):201-203. 被引量:2
  • 4Shulamit S,Golan gerstl R,Rotem K,et al.Alternatively spliced lysyloxidas-like 4 isoforms have a pro metastatic role in cancer[J].ClinExp Metastasis,2013,30 (1):103-117.
  • 5Suk K M,Sung su K,Taek J S,et al.Expression and puri fication of enzymatically active forms of the human lysyl oxi dase like protein 4[J].Journal of Biological Chemistry,2003,278 (52):52071-55207.
  • 6Berlin G V,Guruvayoorappan C.Lysyl oxidase:a potential target for cancer therapy[J].Inflammopharmacology,2011,19 (3):117-129.
  • 7Andreasen P A,Egelund R,Petersen H H.The plasminogen activation system in tumor growth,invasion,and metastasis[J].Cell MolLifeSci,2000,57 (1):25-40.
  • 8Daneri navarro A,Macias lopez G,Oceguera villanueva A,et al.Urokinase type plasminogen activator and plasminogen ac tivator inhibitors (PA-1 and PAI 2) in extracts of invasive cer vical carcinoma and precursor lesions[J].Eur J Cancer,1998,34 (4):566-569.
  • 9Tee Y T,Wang P H,Tsai H T,et al.Genetic polymor phism of urokinase type plasminogen activator is interacting with plasminogen activator inhibito>1 to raise risk of cervical neoplasia[J].J Surg Oncol,2012,106 (2):204-208.
  • 10Nina S,Tibor G.LOXL4 as a selective molecular marker in primary and metastatic head/neck carcinoma[J].Anticancer Res,2010,30 (11):4567-4571.

二级参考文献15

  • 1[1]Engwegen J.Y,Gast M.C,Schellens J.H,et al.Clinical proteomics:searching for better tumour markers with SELDITOFmass spectrometry.Trends Pharmacol.Sci,2006,27:251-259.
  • 2[2]Petricoin E.F,Ornstein D.K,Liotta L.A.Clinical proteomics:Applications for prostate cancer biomarker discovery and detection.Urol.Oncol,2004,22:322-328.
  • 3[3]Banks R.E,Dunn M.J,Hochstrasser D.F,et al.Proteomics:new perspectives,new biomedical opportunities.Lancet,2000,356:1749-1756.
  • 4[4]Stein L.D.Human genome:end of the beginning.Nature,2004,431,:915-916.
  • 5[5]Schnitt S.J.Traditional and newer pathologic factors.J.Natl.Cancer Inst.Monogr,2001,30:22-26.
  • 6[6]Donegan W.L.Tumor-related prognostic factors for breast cancer.CA Cancer J.Clin,1997,47:28-51.
  • 7[7]Alaiya A,Al-Mohanna M,Linder S.Clinical cancer proteomics:promises and pitfalls.J.Proteome Res,2005,4:1213-1222.
  • 8[8]Ariazi EA,Ariazi JL,Cordera F,et al..Estrogen receptors as therapeutic targets in breast cancer.Curr.Top.Med Chem,2006,6:195-216.
  • 9[9]Cai Z,Chiu J.F,He Q.Y.Application of proteomics in the study of tumor metastasis.Genomics Proteomics Bioinformatics,2004,2:152-166.
  • 10[10]Hoehn G.T,Suffredini A.F.Proteomics.Crit.Care Med,2005,33(suppl.):444-448.

共引文献1

同被引文献13

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部